Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nerviano Medical Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2005-000731-26 | P2 |
Completed |
Hepatocellular Carcinoma |
2012-04-19 |
|
| 2006-000798-31 | P2 |
Terminated |
Hepatocellular Carcinoma |
2007-05-16 |